Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for its next phase of growth.

The Company's Board of Directors has unanimously appointed Lisa Wolf to the expanded roles of President and Chief Operating Officer ("COO"), effective immediately. Ms. Wolf will continue to serve as Chief Financial Officer ("CFO") and will assume executive leadership of the Company following the departure of former Chief Executive Officer, Michael K. Handley.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.